Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 1203-1209

  Petko, Zsolt ^g   Ghiassi, Mahan ^a   Shuber, Anthony ^d   Gorham, Janice ^d   Smalley, Walter ^a,c   Washington, M Kay ^a   Schultenover, Stephen ^a,b   Gautam, Shiva ^f   Markowitz, Sanford D ^e   Grady, William M ^c,g,h  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pathology Service   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d Exact Sciences Corporation   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT PROTEIN KINASE INHIBITOR 2A; MOLECULAR MARKER; PROTEIN MLH1; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; BENIGN TUMOR; COLON CANCER; COLON POLYP; COLONOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST; DNA DETERMINATION; FECES ANALYSIS; HUMAN; HUMAN TISSUE; METHYLATION; PRIORITY JOURNAL; UNITED STATES;

ADENOMA; CARRIER PROTEINS; CELL LINE, TUMOR; COLONIC POLYPS; COLORECTAL NEOPLASMS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; FECES; HUMANS; HYPERPLASIA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 19944432471     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101-28.
3. Jass JR, Young J, Leggett BA. Evolution of colorectal cancer: change of pace and change of direction. J Gastroenterol Hepatol 2002;17:17-26.
4. Kinzler K, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
5. Wynter CV, Walsh MD, Higuchi T, et al. Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut 2004;53:573-80.
6. Goldstein NS, Bhanot P, Odish E, Hunter S. Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. Am J Clin Pathol 2003;119:778-96.
7. Rashid A, Shen L, Morris JS, et al. CpG island methylation in colorectal adenomas. Am J Pathol 2001;159:1129-35.
8. Chan AO, Broaddus RR, Houlihan PS, et al. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002;160:1823-30.
9. Lee S, Hwang KS, Lee HJ, et al. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 2004;84:884-93.
10. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004;126:1270-9.
11. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27.
12. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004;363:1283-5.
13. Herman J, Graff J, Myohanen S, et al. Methylation-specific PCR:a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
14. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
15. Willson J, Bittner G, Oberley T, et al. Cell culture of human colon adenomas and carcinomas. Cancer Res 1987;47:2704-13.
16. Grady W, Rajput A, Myeroff L, et al. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998;58:3101-4.
17. Grady WM, Rajput A, Lutterbaugh J, Markowitz S. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001;61:900-2.
18. Shen L, Kondo Y, Hamilton SR, et al. P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology 2003;124:626-33.
19. Ahuja N, Li Q, Mohan M, et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998;58:5489-94.
20. Bariol C, Suter C, Cheong K. et al. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol 2003;162:1361-71.
21. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A 2003;100:8412-7.
22. Moinova HR, Chen WD, Shen L, et al. HLTF gene silencing in human colon cancer. Proc Natl Acad Sci U S A 2002;99:4562-7.
23. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22.
24. Esteller M. Epigenetic lesions causing genetic lesions in human cancer. promoter hypermethylation of DNA repair genes. Eur J Cancer 2000;36:2294-300.
25. Deng G, Chen A, Hong J, et al. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999;59:2029-33.
26. Chan AO, Issa JP, Morris JS, et al. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol 2002;160:529-36.
27. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66.
28. Lofton-Day C, Lesche R. DNA methylation markers in patients with gastrointestinal cancers. Current understanding, potential applications for disease management and development of diagnostic tools. Dig Dis 2003;21:299-308.
29. Nakagawa H, Nuovo GJ, Zervos EE, et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001;61:6991-5.
30. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
31. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
32. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-8.
33. Hixson LJ, Fennerty MB, Sampliner RE, et al. Prospective study of the frequency and size distribution of polyps missed by colonoscopy. J Natl Cancer Inst 1990;82:1769-72.
34. Hermsen M, Postma C, Baak J, et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology 2002;123:1109-19.
35. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-20.
36. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27.
37. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-65.